Managing side effects of immune checkpoint inhibitors in breast cancer

被引：22

作者：

Criscitiello, Carmen ^{[1
,2
]}

Corti, Chiara ^{[1
,2
]}

Pravettoni, Gabriella ^{[2
,3
]}

Curigliano, Giuseppe ^{[1
,2
]}

机构：

[1] IRCCS, European Inst Oncol, Div Early Drug Dev Innovat Therapy, Via Ripamonti 435, I-20141 Milan, Italy

[2] Univ Milan, Dept Oncol & Haematol DIPO, Milan, Italy

[3] IRCCS, European Inst Oncol, Appl Res Div Cognit & Psychol Sci, Milan, Italy

来源：

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2021年 / 162卷

关键词：

Immunotherapy; Adverse events; Management; Immune checkpoint inhibitors; Breast cancer; TUMOR-INFILTRATING LYMPHOCYTES; NIVOLUMAB PLUS IPILIMUMAB; ADVERSE EVENTS; PHASE-III; METASTATIC MELANOMA; DEATH; PROGNOSTIC VALUE; PREDICTIVE-VALUE; DOUBLE-BLIND; OPEN-LABEL;

D O I：

10.1016/j.critrevonc.2021.103354

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Immune-checkpoint inhibitors (ICIs) represent a major development in cancer therapy. The indications for these agents continue to expand across malignancies and disease settings. For years breast cancer (BC) has been considered immunologically quiescent compared with other tumor types. However, recent findings highlighted the immunogenicity of some BCs and paved the way for clinical trials of immunotherapy in BC that led to recent landmark approvals. As a drawback, the safety profile of ICIs is shaped by a specific spectrum of immune-related adverse events (irAEs) that can vary according to ICI class and tumor histology. This review will discuss the epidemiology of these adverse events, their kinetics, risk factors and the most important aspects in their management. A particular focus will be put on BC as the current landscape of immunotherapy for this disease is rapidly increasing the number of people treated with ICIs, thus susceptible to irAEs.

引用

页数：12

共 113 条

[1] Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up A Phase 1b Clinical Trial [J].

Adams, Sylvia ;

Diamond, Jennifer R. ;

Hamilton, Erika ;

Pohlmann, Paula R. ;

Tolaney, Sara M. ;

Chang, Ching-Wei ;

Zhang, Wei ;

Iizuka, Koho ;

Foster, Paul G. ;

Molinero, Luciana ;

Funke, Roel ;

Powderly, John .

JAMA ONCOLOGY, 2019, 5 (03) :334-342

[2] Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199 [J].

Adams, Sylvia ;

Gray, Robert J. ;

Demaria, Sandra ;

Goldstein, Lori ;

Perez, Edith A. ;

Shulman, Lawrence N. ;

Martino, Silvana ;

Wang, Molin ;

Jones, Vicky E. ;

Saphner, Thomas J. ;

Wolff, Antonio C. ;

Wood, William C. ;

Davidson, Nancy E. ;

Sledge, George W. ;

Sparano, Joseph A. ;

Badve, Sunil S. .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (27) :2959-+

[3]

[Anonymous], 2019, FDA Approves Atezolizumab for Triple-Negative Breast Cancer

[4] Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial [J].

Ascierto, Paolo A. ;

Del Vecchio, Michele ;

Robert, Caroline ;

Mackiewicz, Andrzej ;

Chiarion-Sileni, Vanna ;

Arance, Ana ;

Lebbe, Celeste ;

Bastholt, Lars ;

Hamid, Omid ;

Rutkowski, Piotr ;

McNeil, Catriona ;

Garbe, Claus ;

Loquai, Carmen ;

Dreno, Brigitte ;

Thomas, Luc ;

Grob, Jean-Jacques ;

Liszkay, Gabriella ;

Nyakas, Marta ;

Gutzmer, Ralf ;

Pikiel, Joanna ;

Grange, Florent ;

Hoeller, Christoph ;

Ferraresi, Virginia ;

Smylie, Michael ;

Schadendorf, Dirk ;

Mortier, Laurent ;

Svane, Inge Marie ;

Hennicken, Delphine ;

Qureshi, Anila ;

Maio, Michele .

LANCET ONCOLOGY, 2017, 18 (05) :611-622

[5]

Avelumab injection, US NAT LIB MED

[6] Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens A Systematic Review and Meta-analysis [J].

Barroso-Sousa, Romualdo ;

Barry, William T. ;

Garrido-Castro, Ana C. ;

Hodi, F. Stephen ;

Min, Le ;

Krop, Ian E. ;

Tolaney, Sara M. .

JAMA ONCOLOGY, 2018, 4 (02) :173-182

[7] Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4 [J].

Beck, Kimberly E. ;

Blansfield, Joseph A. ;

Tran, Khoi Q. ;

Feldman, Andrew L. ;

Hughes, Marybeth S. ;

Royal, Richard E. ;

Kammula, Udai S. ;

Topalian, Suzanne L. ;

Sherry, Richard M. ;

Kleiner, David ;

Quezado, Martha ;

Lowy, Israel ;

Yellin, Michael ;

Rosenberg, Steven A. ;

Yang, James C. .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (15) :2283-2289

[8] Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy [J].

Bowyer, S. ;

Prithviraj, P. ;

Lorigan, P. ;

Larkin, J. ;

McArthur, G. ;

Atkinson, V. ;

Millward, M. ;

Khou, M. ;

Diem, S. ;

Ramanujam, S. ;

Kong, B. ;

Liniker, E. ;

Guminski, A. ;

Parente, P. ;

Andrews, M. C. ;

Parakh, S. ;

Cebon, J. ;

Long, G. V. ;

Carlino, M. S. ;

Klein, O. .

BRITISH JOURNAL OF CANCER, 2016, 114 (10) :1084-1089

[9] Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline [J].

Brahmer, Julie R. ;

Lacchetti, Christina ;

Schneider, Bryan J. ;

Atkins, Michael B. ;

Brassil, Kelly J. ;

Caterino, Jeffrey M. ;

Chau, Ian ;

Ernstoff, Marc S. ;

Gardner, Jennifer M. ;

Ginex, Pamela ;

Hallmeyer, Sigrun ;

Chakrabarty, Jennifer Holter ;

Leighl, Natasha B. ;

Mammen, Jennifer S. ;

McDermott, David F. ;

Naing, Aung ;

Nastoupil, Loretta J. ;

Phillips, Tanyanika ;

Porter, Laura D. ;

Puzanov, Igor ;

Reichner, Cristina A. ;

Santomasso, Bianca D. ;

Seigel, Carole ;

Spira, Alexander ;

Suarez-Almazor, Maria E. ;

Wang, Yinghong ;

Weber, Jeffrey S. ;

Wolchok, Jedd D. ;

Thompson, John A. .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (17) :1714-+

[10] Classical pathology and mutational load of breast cancer - integration of two worlds [J].

Budczies, Jan ;

Bockmayr, Michael ;

Denkert, Carsten ;

Klauschen, Frederick ;

Lennerz, Jochen K. ;

Gyorffy, Balazs ;

Dietel, Manfred ;

Loibl, Sibylle ;

Weichert, Wilko ;

Stenzinger, Albrecht .

JOURNAL OF PATHOLOGY CLINICAL RESEARCH, 2015, 1 (04) :225-238

← 1 2 3 4 5 6 7 8 9 10 →